Triple therapy prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT)
Current status– recruiting
TRIDENT is an international medical research study which aims to determine the effect of more intensive blood pressure control to prevent recurrent stroke in patients who have had an intracerebral haemorrhage (ICH) (a stroke caused by ruptured blood vessel in the brain). The aim of this project is to test the superiority of a fixed low-dose combination blood pressure-lowering pill (Triple Pill) strategy in recurrent stroke in patients with a history of ICH.
Acute ICH accounts for at least 10% of the 20 million new strokes in the world each year. ICH survivors are at high risk of recurrent stroke and other serious cardiovascular events. Numerous studies have proven the benefit of stroke survivors reducing their risk of recurrent stroke through taking blood pressure-lowering medications. However, studies have shown that many ICH survivors are either not receiving any blood pressure-lowering medication or they are receiving inadequate control.
The TRIDENT Study will be conducted in Australia, the UK, The Netherlands, Sri Lanka, Taiwan, Malaysia and Japan, with expansion to other regions imminent. The study aims to recruit 4,200 patients from 150 centres around the world.
TRIDENT Team Members:
- Craig Anderson – Lead
- Clara Chow – Lead
- Ruth Freed – Global Project Manager
- Joyce Lim – Australasia Project Manager
- Cheryl Carcel – Clinical Research Fellow
- Natalie Espinosa – Senior Clinical Research Associate
- Tina Cheung – Senior Project Officer
- Annie Gao – Project Officer
- Grace Balicki – Project Officer